Express Mail Label No.: ET176335165US

Date of Deposit: April 4, 2002

PATENT APPLICATION Attorney Docket No. 24024-501

THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATES:

Peled et al.

SERIAL NUMBER

09/463,320

EXAMINER:

D. Saunders

FILING DATE:

January 22, 2000

ART UNIT:

1644

For:

METHODS OF CONTROLLING PROLIFERATION AND DIFFERENTIATION OF STEM AND PROGENITOR CELLS

April 4, 2002 Boston, MA

Box DAC

Commissioner for Patents Washington, D.C. 20231

RECEIVED

OFFICE OF PETITIONS

RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE LISTING REQUIREMENTS

In response to the Notice to Comply with Sequence Listing Requirements, mailed June 20, 2001 in the above mention application, Applicants submit a copy of the Notice to Comply, an initial computer readable form (CRF) copy of the "Sequence Listing", a substitute paper copy of the Sequence Listing, a statement that the content of the paper and computer readable copies are the same, and an Amendment directing incorporation of the Sequence Listing into the Specification.

CONCLUSION

The Commissioner is authorized to charge any additional fees due, or credit any overpayment of same, to the undersigned's account, Deposit Account No. 50-0311, Reference No. 24024-501.

JJ.S.S.N.: 09/463,320 Filed: Jahuary 22, 2000

The Examiner is encouraged to call the undersigned below with any questions or comments related to this filing.

Respectfully submitted,

Date: April 4, 2002

Ivor R. Elrifi, Reg. No. 39,529

Attorney for Applicants c/o MINTZ, LEVIN
One Financial Center

Boston, Massachusetts 02111 Tel: (617) 542-6000

Tel: (617) 542-6000 Fax: (617) 542-2241

TRA 1630143v1

Aprilication No.: 69/463 326


NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may b obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

×	attention is directed to the final rulemaking	the requirements of 37 C.F.R. 1.821-1.825. Applicant's notice published at 55 FR 18230 (May 1, 1990), and 111 g date is on or after July 1, 1998, see the final rulemakin 1998) and 1211 OG 82 (June 23, 1998).
	This application does not contain, as a sepa Listing" as required by 37 C.F.R. 1.821(c).	arate part of the disclosure on paper copy, a "Sequence
M	3. A copy of the "Sequence Listing" in compute 37 C.F.R. 1.821(e).	er readable form has not been submitted as required by
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."	
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).	
	6. The paper copy of the "Sequence Listing" is "Sequence Listing" as required by 37 C.F.R.	not the same as the computer readable from of the 1.821(e).
П	7. Other:	RECEIVED
	·	APR 0 9 2002
Аp	plicant Must Provide:	OFFICE OF PETITIONS
X	An initial or substitute computer readable form	(CRF) copy of the "Sequence Listing".
X	An initial or substitute paper copy of the "Seque into the specification.	ence Listing", as well as an amendment directing its entry
囚	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).	
For	questions regarding compliance to thes	
For For	Rul s Interpretation, call (703) 308-421 CRF Submission Help, call (703) 308-4 entin Software Program Support	6 212
•	Technical Assistance To Purchase Patentin Software	703-287-0200 703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY



<110> Peled, Toke Fibach, Eitanger

<120> Methods of Controlling Proliferation and Differentiation of Stem and Progenitor Cells

```
<130> 24024-501
```

<140> 09/463,320

<141> 2000-01-22

<150> PCT/IL9900444

<151> 1999-08-17

<150> 09/161,659

<151> 1998-09-29

<150> 09/130,367

<151> 1998-08-07

<150> 09/024,195

<151> 1998-02-17

<160> 2

<170> PatentIn Ver. 2.1

<210> 1

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
 Peptide

<400> 1

Gly His Lys

1

<210> 2

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<400> 2

Gly Gly His

1

RECEIVED

APR 0 9 2002

OFFICE OF PETITIONS

Express Mail Label No.: ET176335165US Date of Deposit: April 4, 2002

PATENT APPLICATION Attorney Docket No. 24024-501

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Peled et al.

BADENA SERIAL NUMBER:

09/463,320

EXAMINER:

D. Saunders

FILING DATE:

January 22, 2000

ART UNIT:

1644

FOR:

METHODS OF CONTROLLING PROLIFERATION AND

DIFFERENTIATION OF STEM AND PROGENITOR CELLS

April 4, 2002 Boston, MA

Box DAC

Commissioner for Patents Washington, D.C. 20231

STATEMENT IN SUPPORT OF COMPUTER READABLE FORM SUBMISSION UNDER 37 C.F.R. § 1.821(f)

I hereby state that the content of the paper and computer readable forms of the Sequence Listing, submitted in the above-identified application in accordance with 37 C.F.R. § 1.821(c) and 1.821(e), respectively, are the same. No new matter is added at this time.

Respectfully submitted,

Date: April 4, 2002

Ivor R. Elriff, Reg. No. 39,529

Barry J. Marenberg, Reg. No. 40,715

Attorney for Applicants c/o MINTZ, LEVIN One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000

Fax: (617) 542-2241

TRA 1630171v1